Jeffrey Robert Ajer net worth and biography

Jeffrey Ajer Biography and Net Worth

Jeff Ajer joined BioMarin in August 2005 and currently serves as our Executive Vice President and Chief Commercial Officer. From October 2012 to January 2014, Mr. Ajer served as our Senior Vice President and Chief Commercial Officer. From April 2009 to October 2012, Mr. Ajer served as our Vice President, Commercial Operations, The Americas, where he had responsibility for commercial operations throughout the Americas and led product marketing, reimbursement, and sales operations for BioMarin. Prior to joining BioMarin, Mr. Ajer served in various roles at Genzyme Corporation (Genzyme) beginning in November 2003, most recently as Vice President, Global Transplant Operations from December 2004 to August 2005. Mr. Ajer’s experience prior to Genzyme includes roles in sales, marketing and operations at SangStat Medical Corporation and ICN Pharmaceuticals. Mr. Ajer received both a B.S. in chemistry and an M.B.A. from the University of California, Irvine. Mr. Ajer is currently a director of Nektar Therapeutics, a public biopharmaceutical company.

What is Jeffrey Robert Ajer's net worth?

The estimated net worth of Jeffrey Robert Ajer is at least $4.20 million as of November 2nd, 2022. Mr. Ajer owns 41,088 shares of BioMarin Pharmaceutical stock worth more than $4,204,535 as of December 9th. This net worth evaluation does not reflect any other investments that Mr. Ajer may own. Additionally, Mr. Ajer receives an annual salary of $1,200,000.00 as EVP at BioMarin Pharmaceutical. Learn More about Jeffrey Robert Ajer's net worth.

How old is Jeffrey Robert Ajer?

Mr. Ajer is currently 60 years old. There are 4 older executives and no younger executives at BioMarin Pharmaceutical. The oldest executive at BioMarin Pharmaceutical is Mr. Jean-Jacques Bienaime M.B.A., MBA, Chairman & CEO, who is 69 years old. Learn More on Jeffrey Robert Ajer's age.

What is Jeffrey Robert Ajer's salary?

As the EVP of BioMarin Pharmaceutical Inc., Mr. Ajer earns $1,200,000.00 per year. There are 3 executives that earn more than Mr. Ajer. The highest earning executive at BioMarin Pharmaceutical is Mr. Jean-Jacques Bienaime M.B.A., MBA, Chairman & CEO, who commands a salary of $3,670,000.00 per year. Learn More on Jeffrey Robert Ajer's salary.

How do I contact Jeffrey Robert Ajer?

The corporate mailing address for Mr. Ajer and other BioMarin Pharmaceutical executives is 770 Lindaro Street, San Rafael CA, 94901. BioMarin Pharmaceutical can also be reached via phone at (415) 506-6700 and via email at [email protected] Learn More on Jeffrey Robert Ajer's contact information.

Has Jeffrey Robert Ajer been buying or selling shares of BioMarin Pharmaceutical?

During the past quarter, Jeffrey Robert Ajer has sold $258,360.00 in BioMarin Pharmaceutical stock. Most recently, Jeffrey Robert Ajer sold 3,000 shares of the business's stock in a transaction on Wednesday, November 2nd. The shares were sold at an average price of $86.12, for a transaction totalling $258,360.00. Following the completion of the sale, the executive vice president now directly owns 41,088 shares of the company's stock, valued at $3,538,498.56. Learn More on Jeffrey Robert Ajer's trading history.

Who are BioMarin Pharmaceutical's active insiders?

BioMarin Pharmaceutical's insider roster includes Jeffrey Ajer (EVP), Jean Bienaime (CEO), George Davis (EVP), Willard Dere (Director), Henry Fuchs (Insider), Michael Grey (Director), Charles Guyer (EVP), V. Lawlis (Director), Richard Meier (Director), Brian Mueller (CFO), David Pyott (Director), and Dennis Slamon (Director). Learn More on BioMarin Pharmaceutical's active insiders.

Are insiders buying or selling shares of BioMarin Pharmaceutical?

In the last twelve months, BioMarin Pharmaceutical insiders bought shares 1 times. They purchased a total of 3,625 shares worth more than $314,468.75. In the last twelve months, insiders at the biotechnology company sold shares 30 times. They sold a total of 201,605 shares worth more than $17,237,099.42. The most recent insider tranaction occured on December, 2nd when CFO Brian Mueller sold 7,001 shares worth more than $731,604.50. Insiders at BioMarin Pharmaceutical own 1.8 % of the company. Learn More about insider trades at BioMarin Pharmaceutical.

Information on this page was last updated on 12/2/2022.

Jeffrey Robert Ajer Insider Trading History at BioMarin Pharmaceutical

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/2/2022Sell3,000$86.12$258,360.0041,088View SEC Filing Icon  
8/11/2022Sell3,000$95.62$286,860.0044,088View SEC Filing Icon  
5/26/2022Sell1,308$78.94$103,253.5254,109View SEC Filing Icon  
4/13/2022Sell1,180$82.47$97,314.6055,077View SEC Filing Icon  
3/29/2022Sell1,618$79.43$128,517.74View SEC Filing Icon  
3/23/2022Sell6,129$81.78$501,229.62View SEC Filing Icon  
10/26/2021Sell2,739$73.60$201,590.40View SEC Filing Icon  
4/8/2021Sell1,537$78.81$121,130.9758,250View SEC Filing Icon  
3/24/2021Sell1,181$76.30$90,110.3061,439View SEC Filing Icon  
3/18/2021Sell1,308$77.99$102,010.9264,133View SEC Filing Icon  
10/14/2020Sell2,121$79.91$169,489.1161,281View SEC Filing Icon  
6/19/2020Sell15,000$124.00$1,860,000.0063,402View SEC Filing Icon  
4/8/2020Sell2,407$79.98$192,511.8663,064View SEC Filing Icon  
4/1/2020Sell1,537$82.00$126,034.0065,471View SEC Filing Icon  
3/24/2020Sell2,041$74.36$151,768.7668,626View SEC Filing Icon  
3/21/2019Sell4,519$89.98$406,619.6256,659View SEC Filing Icon  
3/19/2019Sell3,728$93.07$346,964.9659,248View SEC Filing Icon  
11/14/2018Sell9,000$92.15$829,350.0058,135View SEC Filing Icon  
10/3/2018Sell1,000$98.98$98,980.0049,135View SEC Filing Icon  
6/11/2018Sell1,436$90.31$129,685.1650,135View SEC Filing Icon  
5/7/2018Sell309$85.96$26,561.6453,223View SEC Filing Icon  
4/2/2018Sell2,119$80.12$169,774.2852,914View SEC Filing Icon  
3/29/2018Sell1,537$79.69$122,483.5355,033View SEC Filing Icon  
3/21/2018Sell4,368$83.90$366,475.2060,153View SEC Filing Icon  
3/9/2018Sell2,972$82.39$244,863.0855,332View SEC Filing Icon  
9/22/2017Sell3,521$95.00$334,495.0049,299View SEC Filing Icon  
6/7/2017Sell1,004$89.61$89,968.4447,944View SEC Filing Icon  
5/2/2017Sell302$96.74$29,215.4851,834View SEC Filing Icon  
3/29/2017Sell3,890$89.15$346,793.5051,532View SEC Filing Icon  
3/7/2017Sell5,000$90.56$452,800.0046,510View SEC Filing Icon  
9/27/2016Sell18,467$95.61$1,765,629.8741,342View SEC Filing Icon  
5/3/2016Sell415$86.03$35,702.4563,487View SEC Filing Icon  
3/4/2016Sell1,255$88.42$110,967.1048,137View SEC Filing Icon  
7/20/2015Sell3,000$150.00$450,000.00View SEC Filing Icon  
6/4/2015Sell1,362$122.35$166,640.70View SEC Filing Icon  
6/1/2015Sell377$123.76$46,657.52View SEC Filing Icon  
5/26/2015Sell1,625$126.55$205,643.75View SEC Filing Icon  
11/3/2014Sell47$83.54$3,926.38View SEC Filing Icon  
5/16/2014Sell1,004$56.91$57,137.6420,980View SEC Filing Icon  
5/13/2013Sell1,248$69.26$86,436.48View SEC Filing Icon  
See Full Table

Jeffrey Robert Ajer Buying and Selling Activity at BioMarin Pharmaceutical

This chart shows Jeffrey Robert Ajer's buying and selling at BioMarin Pharmaceutical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioMarin Pharmaceutical Company Overview

BioMarin Pharmaceutical logo
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Read More

Today's Range

Now: $102.33
Low: $102.28
High: $104.46

50 Day Range

MA: $90.72
Low: $80.93
High: $105.56

2 Week Range

Now: $102.33
Low: $70.73
High: $106.72

Volume

815,511 shs

Average Volume

1,247,442 shs

Market Capitalization

$18.98 billion

P/E Ratio

243.64

Dividend Yield

N/A

Beta

0.37